期刊文献+

头孢哌酮/舒巴坦对临床常见革兰阴性杆菌抗菌活性的研究 被引量:8

Antibacterial activities of different concentrations of cefoperazone-sulbactam against common clinical gram-negative bacilli
原文传递
导出
摘要 目的了解头孢哌酮/舒巴坦对临床常见革兰阴性杆菌的抗菌活性,比较不同浓度的头孢哌酮/舒巴坦纸片药敏试验结果的差异。方法用头孢哌酮/舒巴坦含量75/75(150)和75/30(105)两种药敏纸片对临床分离的216株革兰阴性杆菌,进行K-B法检测同时用琼脂稀释法检测头孢哌酮/舒巴坦(1:1)的最低抑菌浓度(MIC),并采用SPSS统计软件对实验结果进行分析。结果头孢哌酮/舒巴坦105浓度和150浓度纸片法检测鲍氏不动杆菌、大肠埃希菌、肺炎克雷伯菌、嗜麦芽窄食单胞菌和铜绿假单胞菌,两种浓度纸片的符合率分别为30.8%,75.5%,89.4%,90.0%和79.4%;其中符合率最差的是鲍氏不动杆菌,150浓度纸片的敏感率和中介率均增加,耐药率下降,与105浓度纸片比较差异均有统计学意义(P<0.05);对2组抑菌环直径进行配对t检验,差异主要来自于鲍氏不动杆菌(P<0.05)。结论目前临床药敏实验使用的150浓度的纸片法提高了细菌的敏感性,特别是鲍氏不动杆菌的敏感性。 OBJECTIVE To understand the antibacterial activity of cefoperazone-sulbactam against common clinical gram-negative bacilli and compare the results of drug susceptibility testing for different concentrations of cefopera- zone-sulbactam disc. METHODS The drug susceptibility testings of 216 clinical gram-negative bacilli isolates to two kinds of drug susceptibility discs; 75μg/disc cefoperazone plus with 75μg/ disc sulbactam (150 disc) and 75μg/ disc cefoperazone plus with 309g/disc sulbactam (105 disc), were conducted by using K-B method; the minimal inhibitory concentration (MIC) of cefoperazone-sulbactam (1:1) was determined by means of agar dilution meth- od, and the results of the testings were statistically analyzed with the use of SPSS software. RESULTS As for the detection of the Acinetobacter baurnannii , Escherichia coli , Klebsiella pneumoniae , Stenotrophomonas maltophilia, and Pseudornonas aeruginosa, the accordance rates of the cefoperazone-sulbactam 105 disc and cefoperazone- sulbactam 150 disc were 30.8% ,75.5% ,89.4% ,90.0%, and 79.4%, respectively; the accordance rate of detec- tion of the A. baumannii was the lowest. Both the drug susceptibility rate and intermediate rate of the 150 disc were increased, the drug resistance rates were decreased, as compared with the 105 disc, there was significant difference (P〈0. 05). The matching t test was conducted for the inhibition zone diameters between the two groups, and the results showed that the A. baumannii varied significantly in the inhibition zone diameters (P〈0. 05). CONCLUSION The 150 disc that is used for the clinical drug susceptibility testing at present leads to the in- crease of sensitivity of the bacteria, especially the sensitivity of the A. baumannii.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第21期4855-4858,共4页 Chinese Journal of Nosocomiology
基金 温州市科技局科研基金资助项目(Y20130286)
关键词 头孢哌酮/舒巴坦 105纸片/150纸片 K-B法 琼脂稀释法 抗菌活性 Cefoperazone-sulbactam 105 disc/150 disc K-B method Agar dilution method Antibacterial activity
  • 相关文献

参考文献9

  • 1Cai JC,Zhon Hw,Zhang R,et al.Emergence of Serratiamarcescens,Klebsiella pneumoniae,and Escherichia coli iso-lates possessing the plasmid-mediated carbapenem-hydroly-zing beta-lactamase KPC-2in intensive care units of a Chinesehospital[J].Antimicrob Agents Chemother,2008,52(6):2014-2018.
  • 2Marchahn D,Navon-Venezia S,Schwaber MJ,et al.Isolationof imipenem-resistant Enterobacter species:emergence ofKPC-2carbapenemase,molecular characterization,epidemiol-ogy,and outcomes[J].Antimicrob Agents Chemother,2008,52(4):1413-1418.
  • 3Lob SH,Badal RE,Bouchillon SK,[et al].Epidemiology and suscep-tibility of gram-negative appendicitis pathogens:SMART 2008-2010[J].Surg Infect(Larchmt),2013,14(2):203-208.
  • 4刘双全,匡艳华,王巍巍,等.头孢哌酮/舒巴坦对非发酵革兰阴性杆菌的抗菌活性[J].中华医院感染学杂志,2011,19(20):3091-3093.
  • 5Poudyal N,Gyawali N,Gurung R,et al.In vitro activity ofcefoperazone-sulbactam combination against gram negative ba-cilli[J].Nepal Med Coll J,2012;14(1):5-8.
  • 6朱丽莎,艾彪,杜昆,王凤玲.肠杆菌科细菌对头孢哌酮/舒巴坦的耐药性分析[J].中华医院感染学杂志,2012,22(4):809-810. 被引量:6
  • 7邓荣界.头孢哌酮/舒巴坦对常见革兰阴杆菌的体外抗菌作用[J].中外医疗,2014,33(19):129-130. 被引量:5
  • 8卢雅敏,邹安庆,侯佳惠,费静娴,郭美艳,曹建明.鲍曼不动杆菌对头孢哌酮/舒巴坦的体外药敏试验结果评价[J].中国抗生素杂志,2011,36(11):872-874. 被引量:15
  • 9Pei G,Mao Y,Sun Y.In vitro activity of minocycline aloneand in combination with cefoperazone-sulbactam against car-bapenem-resistant Acinetobacter baumannii [J].Microb DrugResist,2012,18(6):574-577.

二级参考文献23

  • 1张婴元,张敬德,周乐,吴培澄,陈友娣,王宇倩,汪复.头孢哌酮-舒巴坦体外抗菌作用研究[J].中华内科杂志,1995,34(10):676-679. 被引量:52
  • 2李娅娟,刘蓬蓬,李萍,孙伟伟,郝晓佳.头孢哌酮/舒巴坦对革兰阴性菌的抗菌活性[J].中华医院感染学杂志,2006,16(5):554-556. 被引量:40
  • 3冯加喜,林云,吕冬青.耐亚胺培南鲍氏不动杆菌医院获得性肺部感染危险因素及耐药性分析[J].中华医院感染学杂志,2006,16(12):1416-1418. 被引量:26
  • 4吴文汉.ICU病房洋葱伯克霍尔德菌三年监测结果的分析[J].检验医学,2007,22(3):262-262. 被引量:8
  • 5Jun Y C, Chang O K, Yoon S P, et al. Comparison of efficacyof cefoperazone-sulbactam and imipenem/cilastatin for treatment of Acinetobacter baumannii[J]. Yonsei Med J, 2006, 47(1): 63-269.
  • 6Jawad A, Heritage J, Snelling A M, et al. Influence ofrelative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces[J]. J Clin Microbiol, 1996, 34(12): 2881.
  • 7Wendt C, Dietze B, Dietz E, et al. Survival of Acinetobacter baumannii on dry surfaces[J]. J Clin Microbiol, 1997,35(6): 1394-1397.
  • 8Beggs C B, Kerr K G, Snelling A M, et al. Acinetobacter spp. and the clinical environment[J], lndoor Built Environ, 2006, 15(1): 19.
  • 9Levin A S. Multiresistant Acinetobacter infections: A role forsulbactam combinations in overcoming an emerging worldwide problem[J]. Clin Microbiollnfect, 2002, 8(3): 144-153.
  • 10NCCLS. Performance standards for antimicrobial susceptibil-ity testing [S]. Fifteenth informational supplement. M100-S15 [J].National Committee for Clinical Laboratory Standards,2010,25(1):34-42.

共引文献23

同被引文献82

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部